Navigation Links
Pharmasset Reports Positive Results from its HCV Clinical Programs
Date:1/6/2011

gic collaboration with Roche. Our other clinical stage HCV candidates include PSI-7977, an unpartnered uracil nucleotide analog that is in two Phase 2b studies in patients with HCV genotypes 1, 2, or 3, and PSI-938, an unpartnered guanine nucleotide analog which has completed a 14-day monotherapy study and has recently initiated a 14-day combination study with PSI-7977. We also have in our pipeline an additional purine nucleotide analog, PSI-661, in advanced preclinical development.

Pegasys(R) and Copegus(R) are registered trademarks of Roche. ContactRichard E. T. Smith, Ph.D.VP, Investor Relations and Corporate CommunicationsOffice +1 (609) 613-4181 Forward-Looking StatementsPharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:  Statements in this press release that are not historical facts are "forward-looking statements," that involve risks, uncertainties, and other important factors, including, without limitation,  the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates,  the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed and commercialized.  For a discussion of risks, uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended September 30, 2010 filed with the Securities and Exchange Commission and discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Se
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 2015   Heska Corporation  (NASDAQ:  HSKA -  News ... advanced veterinary diagnostic and other specialty veterinary products ... Element i ® Immunodiagnostic Analyzer. Element i ... health concerns, including thyroid disorders, Cushing,s disease and ... bench top analyzer that delivers rapid immunoassay testing, ...
(Date:7/28/2015)... July 28, 2015  Psychemedics Corporation (NASDAQ: PMD ... period ended June 30, 2015.  The Company also announced ... shareholders of record as of August 7, 2015 to ... the Company,s 76 th consecutive quarterly dividend. ... 30, 2015 was $7.0 million versus $7.7 million for ...
(Date:7/28/2015)... 2015  Nevro Corp. (NYSE: NVRO ), ... innovative evidence-based solutions for the treatment of chronic ... results in the Online First edition of ... of Anesthesiologists. The SENZA-RCT pivotal ... first to directly compare spinal cord stimulation (SCS) ...
Breaking Medicine Technology:Heska Announces Veterinary Market's first and only point of care Analyzer for TSH, Total T4, and Cortisol results in minutes 2Heska Announces Veterinary Market's first and only point of care Analyzer for TSH, Total T4, and Cortisol results in minutes 3Psychemedics Corporation Announces Second Quarter Earnings 2Psychemedics Corporation Announces Second Quarter Earnings 3Psychemedics Corporation Announces Second Quarter Earnings 4Psychemedics Corporation Announces Second Quarter Earnings 5Psychemedics Corporation Announces Second Quarter Earnings 6Psychemedics Corporation Announces Second Quarter Earnings 7Psychemedics Corporation Announces Second Quarter Earnings 8Nevro Announces Publication of SENZA-RCT Results in Anesthesiology 2
... Life Sciences, Inc. (Nasdaq: CALP ) ... co-marketing agreement which will leverage Covaris, acoustic DNA ... to develop automated workflows for next generation sequencing ... solutions for library construction, sample analysis, and nucleic ...
... N.J., Feb. 23, 2011 PDI, Inc. (Nasdaq: ... executive officer, is scheduled to present at the Cowen and Company ... 9, 2011 at the Marriott Copley Place in Boston. ... Relations" tab on the company,s website at http://www.pdi-inc.com . The ...
Cached Medicine Technology:Caliper and Covaris Establish Co-Marketing Agreement to Simplify Next Generation Sequencing 2Caliper and Covaris Establish Co-Marketing Agreement to Simplify Next Generation Sequencing 3
(Date:7/28/2015)... ... July 28, 2015 , ... The Triumph Modular, Redefining Modular™ ... education, resource library, floor plans, educational blog and wide use of imagery. The ... posts with valuable links to useful reports by industry experts. Comments are welcomed ...
(Date:7/28/2015)... ... July 28, 2015 , ... World Patent ... a new household invention that makes shelling eggs an exact science. , “The ... Scott Cooper, CEO and Creative Director of World Patent Marketing. “With a growth ...
(Date:7/28/2015)... ... July 28, 2015 , ... World Patent ... and Found, a breakthrough technological invention. It is a wearable personal tracking ... electronic industry reached a record high of $211.3 billion in 2014," says Scott ...
(Date:7/28/2015)... ... July 28, 2015 , ... The Denver Foundation and Blair-Caldwell ... and Exhibited,” a photographic and narrative exploration of African American giving, which runs ... neighborhood. , Denver is one of only ten cities to host “The Soul ...
(Date:7/28/2015)... ... July 28, 2015 , ... Morristown Medical Center, part ... and one of the first five hospitals in the nation, to implant the newly ... on July 23, and all are in good condition. , The CoreValve® Evolut® R ...
Breaking Medicine News(10 mins):Health News:Triumph Modular Launches Refreshed Modular Building Industry Website 2Health News:Essential Bang For Your Buck Kitchen Items Presented By World Patent Marketing 2Health News:Essential Bang For Your Buck Kitchen Items Presented By World Patent Marketing 3Health News:Essential Bang For Your Buck Kitchen Items Presented By World Patent Marketing 4Health News:Essential Bang For Your Buck Kitchen Items Presented By World Patent Marketing 5Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 2Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 3Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 4Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 5Health News:"The Soul of Philanthropy Reframed and Exhibited” Comes to Denver 2Health News:Morristown Medical Center First Hospital in New Jersey to Implant Newly Approved Heart Valve 2Health News:Morristown Medical Center First Hospital in New Jersey to Implant Newly Approved Heart Valve 3
... drug currently undergoing human trials in Europe for treating ... cell damage in Duchenne and other forms of muscular ... Hospital Medical Center reported their results using three different ... March 16 by the journal Nature Medicine. , The ...
... 10 cities waive co-pays if diabetic is "coached" by ... taking part in the Diabetes Ten City Challenge showed ... the early stages of the program, according to a ... Association (APhA). , The challenge is an employer-based diabetes ...
... daily,"Profile America" feature from the U.S. Census Bureau:, ... America -- Saturday, March 15th. If you,re feeling tense,perhaps ... to pause,stand back and reflect that there is humor ... the value of laughter and those who make us,laugh. ...
... Guidelines Emphasize Importance of Allergy Testing to Control Chronic ... ... 14 Allergy and asthma specialists,from around the country will gather ... (NAEPP) Guidelines for,the Diagnosis and Management of Asthma. These guidelines are ...
... N.C. Studies have shown that surgery combined with ... select patients with peritoneal carcinoma (cancer of the lining ... or appendix cancer. , Researchers from Wake Forest University ... on the use of IPHC in treating peritoneal cancer ...
... U.S.,Senate confirmed Jeffrey J. Grieco as the Assistant ... Agency for International,Development (USAID)., As head of ... will,manage USAID,s congressional and press relations; outreach to ... mission, objectives and,accomplishments; production of print, video and ...
Cached Medicine News:Health News:Investigational drug tested for preventing muscle fiber death in muscular dystrophy 2Health News:Investigational drug tested for preventing muscle fiber death in muscular dystrophy 3Health News:Self-Management Program Helps Diabetics 2Health News:NIH Asthma Guidelines Will Leave Sufferers Breathing Easier This Spring 2Health News:Researchers study new drug and indications for heated chemotherapy treatment 2Health News:Jeffrey J. Grieco Confirmed as USAID Assistant Administrator for Legislative and Public Affairs 2
... Watchmaker forceps have very fine tips and are ... a microscope is required. The curved ones are ... fine metal shards. The student versions are for ... to be static free. The Swiss forceps are ...
Vertigraft Humerus/Tibia Shaft an Cross-sections with even Anterior and Posterior heights may be processed from either the humerus or tibia. Anterior lumbar interbody fusion, corpectomy. Freeze-drie...
... anterior column support for single or multilevel ... L5. The system consists of one or ... are stacked to a desired height, accommodating ... reinforced polymer material emulates the biomechanical properties ...
... stackable cage system provides anterior column support ... vertebrectomies from T1 to L5. The system ... fiber polymer cages that are stacked to ... The Peek Carbon fiber reinforced polymer material ...
Medicine Products: